United Therapeutics Corporation (UTHR) is a Biotechnology company in the Healthcare sector, currently trading at $578.54. It has a SharesGrow Score of 80/100, indicating a strong investment profile with 5 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of UTHR = $1,320.25 (+128.2% from the current price, the stock appears undervalued). Analyst consensus target is UTHR = $580 (+0.2% upside).
Valuation: UTHR trades at a trailing Price-to-Earnings (P/E) of 19.2 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 1.31.
Financials: revenue is $3.2B, +18.1%/yr average growth. Net income is $1.3B, growing at +22.8%/yr. Net profit margin is 41.9% (strong). Gross margin is 87.9% (-4.5 pp trend).
Balance sheet: total debt is $0 against $7.1B equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 6.6 (strong liquidity). Debt-to-assets is 0%. Total assets: $7.9B.
Analyst outlook: 16 / 30 analysts rate UTHR as buy (53%) — moderate consensus.
SharesGrow 7-Criteria breakdown: Value 54/100 (Partial), Growth 90/100 (Pass), Past 100/100 (Pass), Health 100/100 (Pass), Moat 71/100 (Pass), Future 46/100 (Partial), Income 100/100 (Pass).
